IDEXX Laboratories IDXX
Healthcare · Medical - Diagnostics & Research · Synthos Deep Dive · 2026-07-03
The Overview
IDEXX makes the blood-test machines, test kits, and lab services that veterinarians use to diagnose your dog or cat. Its trick is the classic "razor-and-blade": it places the analyzer in the clinic, then sells the disposable cartridges and lab tests that run on it — over and over, at very high margins. It is the dominant player, it is extremely profitable, and about 60 cents of every sales dollar is gross profit.
The catch: the stock is expensive. Even after falling about 27% from its high, you're paying roughly 41 dollars for every 1 dollar of annual profit — a price that only makes sense if the company grows fast. But growth has cooled to about 10% a year as the pandemic-era boom in pet-vet visits faded. So you're paying a fast-grower price for a steady-grower. Our verdict is Watch — a wonderful company, but wait for a cheaper price before buying.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). The company carries very little debt and is rock-solid financially — but the high price and a stock that has already dropped 27% mean a further stumble could hurt.
- Growth Quality 8/10 (very good). This is a top-tier, highly profitable business with a strong grip on its customers.
- Exponential Potential 3/10 (low). It grows steadily but slowly, and its market (pet diagnostics) has natural limits — don't expect it to multiply quickly.
The one big worry: you're paying a premium price for growth that has slowed. If vet visits stay soft, the stock's price tag could shrink even if the business keeps doing fine.
Putting a number on it: our fair-value estimate is $565 against a current price of $554.99 — real upside if our numbers are right.
Our summary metrics
Fortress balance sheet (net-debt/EBITDA 0.58×) but 41× trailing on ~10% growth, beta 1.54, −27% off highs.
~10% rev / ~15% EPS CAGR, 62% GM, elite 40% ROIC & 71% ROE, razor-and-blade recurring moat.
Durable compounder, not an exponential — growth flat-to-decelerating in a bounded companion-animal TAM.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Durable compounder, not an exponential — growth flat-to-decelerating in a bounded companion-animal TAM.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $747.5 (high $800 / low $640; 13 Buy · 8 Hold · 1 Sell) — context, not our anchor |
| Valuation | 41× trailing EPS · 38× FY26E · 34× FY27E · 21× FY30E · EV/S 10.1× · EV/EBITDA 28.8× |
| Technicals | Downtrend — $557.8, −27% off 52-wk high, below 200-DMA, RSI 50, +2.8% 12-mo (SPY +21%, QQQ +30%) |
| Conviction | Quant-only — 0 expert voices in the Synthos KB; the call rests on fundamentals + valuation |
| Position sizing | Watch-list; if bought, satellite-quality-compounder ~1–3%, only on a better entry |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for IDXX — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $554.99, 1% below the 50-day average ($559), 9% below the 200-day average ($611) — a downtrend. 28% below the 52-week high of $767, 5% above the 52-week low of $526.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $554.99 is currently inside the band (band $533–$599).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 48.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 1.91, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = IDXX · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
IDEXX Laboratories (NASDAQ: IDXX), founded 1983 and headquartered in Westbrook, Maine, is the global leader in companion-animal (pet) veterinary diagnostics. Its economic engine is the Companion Animal Group (CAG): in-clinic analyzers (chemistry, hematology, the SediVue urine analyzer), SNAP rapid-assay test kits, reference-lab diagnostic services, and veterinary practice-management software. Smaller segments cover Water testing (the Colilert/Legiolert microbiology franchise) and Livestock, Poultry & Dairy (LPD). The model is razor-and-blade: analyzers seed the installed base, then high-margin recurring consumables and lab services compound on top. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
- By type: Product $2.54B (59%) · Service $1.76B (41%). The service/recurring tilt is the moat — reference-lab and consumable revenue is sticky and repeats.
- By geography: United States $2.75B (64%) · EMEA ~$1.17B (27%) · Asia-Pacific $356M · Canada $167M · Latin America $90M. US-concentrated, which is a strength (pricing power) and a concentration risk.
The structural story is secular: pet ownership, pet "humanization," and rising diagnostic intensity per visit. The near-term story is cyclical: post-COVID clinical-visit volumes in the US have run soft, and that is what has compressed the growth rate and the stock.
2. The expert thesis — no coverage in the Synthos KB
There is zero expert coverage of IDXX in the Synthos knowledge base (total_claims: 0, breadth 0, net conviction 0). None of the net-bullish voices or the cautionary voice we track has published a traceable claim on this name. This is stated plainly and honestly: the verdict below is fundamentals- and quant-driven, not conviction-driven. Where a name like LLY carries 13 net-bullish voices and 251 reconciled claims, IDXX carries none — so we lean entirely on the reported financials, the analyst-estimate consensus, and our own scenario model. We do not fabricate conviction to fill the gap.
Because there are no claim_ids to cite, no expert quotations appear anywhere in this note.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Fortress balance sheet (net-debt/EBITDA 0.58×, interest coverage 35×) and a recurring-revenue moat cut the business risk — but 41× trailing / 29× EV-EBITDA on ~10% growth, beta 1.54, and a −27% drawdown mean valuation is the risk, not solvency. |
| Growth Quality | 8 · Very High | ~10% forward revenue CAGR, ~15% EPS CAGR, 62% gross margin, 40% ROIC / 71% ROE, and a razor-and-blade recurring moat — elite quality; only the growth rate keeps it off a 9. |
| Exponential Potential | 3 · Low | Growth is roughly flat-to-decelerating (rev +10% FY25 → ~+9% FY26–28E), the companion-animal-diagnostics TAM is bounded, and a $44B cap in a mature category caps the multibagger. A durable compounder, not an exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | US vet-visit volumes recover; new-instrument placements + Cancer Dx / inVue ramp; FY27E EPS beats to ~$18 (vs $16.6 cons); premium multiple holds at ~40×. | ~$720 (+29%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $16.6; a durable ~10% grower with 62% GM and 40% ROIC earns a ~34× multiple. | ~$565 (+1%) |
| Bear | Vet-visit softness persists, competitive pressure on consumables; FY27E EPS misses to ~$15; multiple de-rates toward ~26× as the market re-prices a 10% grower. | ~$390 (−30%) |
Synthos fair value = the base case, ~$565 (+1%), with the full $390–$720 span as the honest range. This anchor sits well below the Street's $747.5 consensus — the Street is applying a mid-40s multiple that we think over-rewards a business now growing ~10%; our base uses a still-premium but more defensible ~34×. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). IDXX is a high-quality compounder with low exponential potential:
- Forward growth (estimates): revenue CAGR FY25→FY30E ~10.2% ($4.30B → $6.98B); EPS CAGR ~14.8% ($13.08 → $26.10E) as buybacks and modest margin gains lever the top line.
- Acceleration (the 2nd derivative) is roughly flat-to-negative: revenue growth +10.4% (FY25) → ~+9.4% (FY26E) → ~+8.8% (FY27E) → ~+9.1% (FY28E), with a modest reacceleration to ~+13.7% only in the FY30E tail (thin analyst count). No inflection — this is steady-state compounding, not a lift-off curve.
- Room to run: the companion-animal-diagnostics TAM is real and secularly growing (pet humanization, diagnostic intensity per visit), but it is bounded — IDXX is already the category leader, so share gains and price/mix, not a greenfield market, drive growth. At $44B the law of large numbers within a mature niche caps the multibagger.
- Reinvestment runway: capex is light (~2.8% of revenue), FCF is strong (~$1.05B FY25), and capital returns run through buybacks (no dividend) — a cash-compounding profile, not a reinvest-for-hypergrowth one.
Exponential Potential: Low (3/10). Own IDXX for durable ~10–15% earnings compounding and best-in-class returns on capital — not for a fast multibagger. That honesty is precisely why the rich multiple matters so much to the verdict.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $4.30B, +10.4% (FY24 $3.90B, +6.5% on FY23 $3.66B). Steady double-digit-ish top line; the pandemic-era mid-teens pace has normalized down.
- Quarterly trajectory: Q1'25 $998M → Q2 $1,109M → Q3 $1,105M → Q4 $1,091M → Q1'26 $1,141M (+14.3% YoY). Q1'26 was a solid reacceleration off a soft-ish 2025.
- Margins: gross 62.1% TTM, EBITDA 35.1%, operating 31.6%, net 24.6% TTM. Elite for a diagnostics/instruments hybrid.
- Returns on capital (the real tell): ROIC 40.3%, ROE 70.9%, ROA 32.4% — top-decile capital efficiency, the mathematical signature of the razor-and-blade moat.
- Earnings: net income $1.06B FY25 (EPS diluted $13.08, GAAP $13.17) vs $888M / $10.67 FY24. Q1'26 EPS diluted $3.45.
- Cash flow: operating CF $1.18B, capex ~−$125M, FCF ~$1.05B FY25 (FCF margin ~24%). Capital-light and cash-generative.
- Balance sheet: total debt ~$1.08B, cash $180M, net debt ~$897M, net-debt/EBITDA 0.58× — barely levered, interest coverage ~35×. The financial-risk side of the ledger is pristine.
6. Valuation — priced in or room?
This is the whole debate. There is no way to call IDXX cheap: 41× trailing EPS, 10.1× sales, 28.8× EV/EBITDA, 28.7× book. FMP's own model flags it (P/E score 1/5, P/B score 1/5, D/E score 1/5) even while rewarding the returns (ROE/ROA 5/5). The bull's defense is multiple compression through growth: on live consensus the forward P/E is 38× (FY26E) → 34× (FY27E) → 29× (FY28E) → 21× (FY30E) — the multiple does fall as EPS compounds, if estimates hit. But a PEG north of 3 (trailing PEG 1.6, forward PEG ~3.1 per FMP) says you are paying a rich price for a ~10% grower. A reverse read: today's $557.80 embeds roughly the Street's low-double-digit revenue / mid-teens EPS CAGR with the premium multiple persisting — little margin for a soft-volume year. Street targets (context): consensus $747.5, high $800, low $640 — materially above our $565 base because the Street keeps a mid-40s multiple we think over-rewards the current growth rate. Not a value buy; a quality-at-a-still-full-price name best bought on weakness.
7. Technicals (from the tech block)
- Trend: down. $557.80 sits essentially on the 50-DMA ($555.9) but well below the 200-DMA ($628.1) — the 200 is above the 50, a downtrend posture. MACD −4.5 (negative).
- Location: −27.2% off the 52-week high ($766.68), only +8.4% off the 52-week low ($514.61) — closer to the bottom of the range than the top; max drawdown from peak −27.2%.
- Momentum: RSI(14) 50 — dead neutral, neither oversold nor overbought; no momentum signal either way.
- Relative strength (the tell): IDXX +2.8% 12-mo vs SPY +20.6% and QQQ +30.3%; −18.2% 6-mo vs SPY +8.4%. Persistent, meaningful underperformance of both the market and the Nasdaq-100 — the market has been de-rating this name, not accumulating it.
- Read: technicals do not confirm a buy — this is a broken-uptrend, below-200-DMA chart lagging its index. It argues for patience: a base near the 52-week low, or a reclaim of the 200-DMA, would be a lower-risk entry than chasing here.
8. Moat & competitive position
IDEXX's moat is a textbook razor-and-blade lock-in: (1) a large installed base of in-clinic analyzers that generate recurring, high-margin consumable and reference-lab revenue; (2) switching costs — vets are trained on IDXX workflows, software, and lab integrations, and rip-and-replace is disruptive to a busy practice; (3) scale in the reference-lab network and menu breadth that a subscale rival can't match; (4) a direct sales/field force relationship with practices. The 62% gross margin, 40% ROIC and 71% ROE are the quantitative proof the moat converts to economics. The principal threat is not disruption but volume cyclicality (US vet-visit softness) and gradual consumable-pricing competition.
Peer set (FMP-supplied, market cap): the closest true comp is Zoetis (ZTS) $31B (animal-health, though pharma-tilted). The rest are broader life-science/diagnostics/med-tech names: Agilent $37B, IQVIA $35B, Veeva $31B, Becton Dickinson $57B, Edwards Lifesciences $54B, Alnylam $42B, argenx $58B, Cardinal Health $56B, Cencora $58B. IDXX commands the richest quality metrics (ROIC/ROE) and one of the richest multiples in the group — justified only if the growth and returns persist.
9. Management, capital allocation & guidance
- Capital allocation: disciplined and shareholder-friendly. No dividend; capital returns run almost entirely through buybacks — FY25 repurchased ~$1.22B of stock (net share count fell from ~82.5M to ~80.1M), funded by ~$1.05B FCF plus modest debt. Capex is light (~$125M). This is a cash-compounder that shrinks the share count rather than reinvesting for hypergrowth — appropriate given the 40% ROIC and bounded TAM.
- Insider activity: the sampled window (through 2026-06-02) shows routine activity only — director equity awards/options at ~$534, and an officer (EVP George Fennell) RSU vesting with an in-kind tax withholding at $566.79. No cluster of alarming discretionary open-market selling.
- Management guidance: IDEXX guides organic revenue growth and EPS on its earnings calls; no management voice is in the Synthos KB, so we rely on the FMP analyst-estimate consensus (labeled as estimates throughout) rather than distilled guidance claims. Gap flagged: no IDXX management or expert claims are ingested — this note is quant-only.
10. Catalysts & what to watch
- Next earnings: 2026-08-03 (Q2'26; Street EPS $3.95, revenue ~$1.20B). The key line: US CAG organic growth and clinical-visit volume trends — the single biggest swing factor for the whole thesis.
- New-product ramp: IDEXX Cancer Dx / inVue and next-gen in-clinic platforms — instrument placements and consumable pull-through.
- Pricing & mix: consumable price realization vs volume, and reference-lab share.
- Buyback pace: continued share-count reduction as a per-share EPS lever.
- Multiple: any re-rating (up or down) matters more than usual given the 41× starting point.
Thesis tripwires (what would change the call): two consecutive quarters of accelerating organic growth back toward mid-teens (would move us toward Buy on a pullback); or a break of the 52-week low on sustained volume weakness (would move us toward Avoid). A pullback into the low-$500s that keeps the fundamentals intact is the entry we're waiting for.
11. Key risks
- Valuation / de-rating (the primary risk): 41× trailing on ~10% growth leaves no cushion; a soft-volume year could compress the multiple materially even if the business is fine.
- US vet-visit cyclicality: the model depends on clinical-visit volumes, which have run soft post-COVID and are macro/discretionary-sensitive.
- Concentration: 64% US revenue and a single dominant end-market (companion-animal diagnostics) — narrow relative to a diversified med-tech.
- Competitive pressure on consumables: rivals (incl. Zoetis/Antech and others) chipping at instrument placements or consumable pricing.
- Beta / drawdown: beta 1.54 and an existing −27% drawdown mean the stock can move hard on sentiment.
- No expert corroboration: zero KB coverage — no independent analyst panel to pressure-test the fundamentals-and-quant read.
12. Verdict, position sizing & monitoring
Watch. IDEXX is an unambiguously elite business — 62% gross margin, 40% ROIC, 71% ROE, a durable razor-and-blade moat, a pristine balance sheet, and ~10–15% forward earnings compounding. The problem is entirely price: at 41× trailing on ~10% growth, with the chart in a downtrend below the 200-DMA and lagging its index by ~18–28 points, the risk/reward is roughly neutral (our base fair value ~$565 is ~+1% from spot and below the Street's $747.5). We do not chase quality at any price. Watch it, and buy on a better entry.
- Sizing: watch-list today. If bought, treat as a satellite-quality compounder, ~1–3%, and only into weakness (low-$500s or a 200-DMA reclaim), scaled in rather than lumped.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-08-03). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $557.80.
- Single biggest risk: paying a premium multiple for a business now growing ~10% — a de-rating if vet-visit volumes stay soft.
Provenance & disclosures
- Traceability: 0 KB claims — no expert coverage of IDXX in the Synthos knowledge base. This note is fundamentals- and quant-driven; no
claim_ids are cited because none exist. Fabricated conviction is structurally impossible (nothing to reconcile, and none invented). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").